NASDAQ · COAG
Hemab Therapeutics Holdings, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for COAG: Nov 10, 2026
Hemab Therapeutics Holdings, Inc. Common Stock is estimated to report earnings on 11/10/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.51.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.51 | $-0.45 | $-0.54 | 3 |
| Dec 2026 | $-0.56 | $-0.54 | $-0.57 | 3 |
| Mar 2027 | $-0.54 | $-0.49 | $-0.59 | 2 |
| Jun 2027 | $-0.64 | $-0.63 | $-0.65 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · BNK Invest · MarketBeat- Fintel · Oct 12, 6:24 PM EDTRodman & Renshaw Initiates Coverage of Hemab Therapeutics Holdings with BuyFintel reports that on October 12, 2026, Rodman & Renshaw initiated coverage of Hemab Therapeutics Holdings (NASDAQGS:COAG) with a Buy recommendation. On the day of the coverage initiation, October 12, 2026, the stock closed at $30.35. This follows a pre-action close of $31.6
- RTTNews · Sep 17, 9:01 AM EDTHemab Doses First Participant In Phase 1 HMB-003 Trial For Heavy Menstrual Bleeding(RTTNews) – Hemab Therapeutics Holdings, Inc. (COAG), a clinical-stage biotechnology company developing therapies for blood coagulation disorders, reported on Thursday that it has dosed first participant in a Phase 1 trial of HMB-003, an investigational peptide therapy for heavy
- RTTNews · Aug 14, 4:21 AM EDTBiotech Stocks At 52-Week Highs – PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG(RTTNews) – The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.
- RTTNews · Aug 12, 6:36 AM EDTHemab Therapeutics Q2 Net Loss Widens; Plans To Initiate Phase 3 Trial Of Sutacimig In H2 2026(RTTNews) – Hemab Therapeutics (COAG), a clinical-stage biotechnology company developing therapies for treating blood coagulation disorders, announced financial results for the second quarter of 2026 reflecting a wider net loss. In addition, the company provided an update on its
- RTTNews · Aug 7, 6:30 AM EDTBiotech Stocks At 52-Week Highs – DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX(RTTNews) – The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.
- BNK Invest · Jul 28, 7:21 AM EDTCOAG Crosses Above Average Analyst TargetIn recent trading, shares of Hemab Therapeutics Holdings Inc (Symbol: COAG) have crossed above the average analyst 12-month target price of $50.00, changing hands for $50.39/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: d
- RTTNews · Jul 21, 3:41 AM EDTBiotech Stocks At 52-Week Highs – XNCR, COAG, MNPR, SOPH, ACRS(RTTNews) – The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies.
- RTTNews · Jul 15, 7:08 AM EDTHemab Presents Sutacimig Data; Wedbush Rates Outperform, $55 Target(RTTNews) – Hemab Therapeutics (COAG) presented new clinical and preclinical data for its lead candidate Sutacimig at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, underscoring its potential to transform treatment for Glanzmann thrombasthe
- RTTNews · Jul 14, 4:03 AM EDTBiotech Stocks At 52-Week Highs – COAG, ALMR, PGNY, TXG, VMD(RTTNews) – The following biotech stocks touched a 52-week high on July 14, 2026, attributable to key catalysts like encouraging clinical trial results and the launch of new programs supporting research advancements.
- RTTNews · Jul 13, 1:26 AM EDTHemab Presents Positive HMB-002 Clinical Data In VWD; Unveils HMB-003 For Heavy Menstrual Bleeding(RTTNews) – Hemab Therapeutics (COAG), a clinical-stage biotechnology company, presented new positive clinical data from HMB-002 in Von Willebrand disease (VWD) and announced the HMB-003 program in development for Heavy Menstrual Bleeding at the International Society on Thrombosi
- MarketBeat · Jun 8, 11:03 PM EDTHemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III PlansHemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build
- RTTNews · May 5, 3:31 AM EDTHemab Therapeutics Closes Upsized $346.7 Million IPO To Advance Rare Bleeding Disorder Pipeline(RTTNews) – Shares of Hemab Therapeutics Holdings, Inc. (COAG) began trading on the Nasdaq Global Select Market on May 1, 2026, after the company announced the closing of its upsized initial public offering, raising approximately $346.7 million in gross proceeds.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Hemab Therapeutics Holdings, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.